Sema4, a health information company, will use screening and diagnostic tests and predictive models to help patients, clinicians and researchers predict health trajectories. The company’s focus will include genetic tests developed at Mount Sinai, such as Sema4 Expanded Carrier Screen, which tests for 281 genetic diseases.
Sema4 will comprise a staff of more than 300, including clinicians, engineers and genetic counselors. Eric Schadt, PhD, dean for precision medicine at the Icahn School of Medicine, will serve as CEO.
“We will incorporate patient information — including genetic, environmental, clinical, pharmaceutical and device data — to model the complexity of disease and wellness and to generate more personalized, precise and real-time insights for our patients,” Dr. Schadt said.
More articles on health IT:
IBM brings Watson for Oncology to China
North Dakota health dept. notifies 2.5k Medicaid patients of privacy breach: 5 things to know
OIG: Top HHS management challenges include information security, data integrity
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.